Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Anbio Biotechnology maintains a gross margin of 92.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 73.45%, while the net margin is 82.84%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively NNNN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NNNN competes directly with industry leaders such as LNTH and TFX. With a market capitalization of $2.86B, it holds a significant position in the sector. When comparing efficiency, NNNN's gross margin of 92.32% stands against LNTH's 57.91% and TFX's 49.47%. Such benchmarking helps identify whether Anbio Biotechnology is trading at a premium or discount relative to its financial performance.
